The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Kisunla Eli Lilly Australia Pty Ltd
Product name
Kisunla
Sponsor
Accepted date
Oct-2023
Active ingredients
donanemab
Proposed indication
Is indicated to slow disease progression in adult patients with Alzheimer’s disease.
Application type
A (new medicine)
Publication date
Oct-2023